9 completed, 3 unknown, 2 recruiting, 2 terminated. 9 Phase 2, 4 Phase 3, 1 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Unknown 1 |
| Phase 3 | 4 | Unknown 2, Completed 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Interleukin-11: new trials by email Literature Review of Interleukin-11 trials Research Report on Interleukin-11
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 Romiplostim N01, Recombinant Human Interleukin-11 (rhIL-11) - CTIT: Cancer Therapy Induced Thrombocytopenia | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 88 | 2025-02-24 | 2026-04-14 |
| Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission Venclexta 100 MG Oral Tablet - Acute Myeloid Leukemia | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 100 | 2023-04-12 | 2023-06-18 |
| To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment Recombinant Human Interleukin-11 for Injection - Chemotherapy-induced Thrombocytopenia | Completed | Liaoning Cancer Hospital & Institute | 3494 | 2020-09-02 | 2023-01-18 | |
| Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis Recombinant Human Interleukin-11, Saline - Nasopharyngeal Carcinoma | Phase 3 | Unknown | Zhejiang Cancer Hospital | 300 | 2018-10-01 | 2020-08-11 |
| A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 NL201, rhIL-11 - Chemotherapy-induced Thrombocytopenia | Phase 3 | Completed | Beijing Northland Biotech. Co., Ltd. | 62 | 2015-03-01 | 2020-09-16 |
| Hemostatic Complications in Hematopoietic Stem Cell Transplantation thrombopoietin, interleukin-11, heparin, - Hemostatic Disorders | Unknown | The First Affiliated Hospital of Soochow University | 200 | 2014-12-01 | 2015-10-08 | |
| Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia MPs, thrombopoietin (TPO) and interleukin-11 - Hematological Diseases, Thrombocytopenia | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 250 | 2014-09-01 | 2014-09-16 |
| Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL rhIL-11 - Pancytopenia Due to Chemotherapy | Phase 4 | Completed | Shanghai Children's Medical Center | 120 | 2011-09-01 | 2014-12-11 |
| Efficacy and Safety of IL-11 in DDAVP Unresponsive Neumega (Oprelvekin, Interleukin 11, IL-11) - Hemophilia A, Von Willebrand Disease | Phase 2 | Completed | University of Pittsburgh | 9 | 2010-01-01 | 2016-03-02 |
| IL-11 in Adults With Von Willebrand Disease Undergoing Surgery Neumega (Oprelvekin, Interleukin 11, IL-11) - Von Willebrand Disease | Phase 2 | Terminated | Margaret Ragni | 3 | 2008-02-01 | 2019-06-11 |
| IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia Oprelvekin, Interleukin 11, IL-11 - Von Willebrand Disease | Phase 2 | Completed | Margaret Ragni | 7 | 2008-01-01 | 2018-01-31 |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients Interleukin-11 (IL-11 or Neumega) - Leukemia, Chronic Myelogenous Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 8 | 2005-10-01 | 2012-02-20 |
| Phase II Study of IL-11 (Neumega) in Von Willebrand Disease recombinant interleukin-11 - Von Willebrand Disease | Phase 2 | Completed | University of Pittsburgh | 12 | 2004-07-01 | 2016-05-17 |
| Study Evaluating rhIL-11 in Active Crohn's Disease Recombinant Human Interleukin-11 (rhIL-11) - Crohn Disease, Inflammatory Bowel Disease | Phase 2 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-04-01 | 2013-02-08 | |
| Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma rituximab, yttrium Y 90 ibritumomab tiuxetan, indium In 111 ibritumomab tiuxetan - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 81 | 2001-04-01 | 2018-08-09 |
| Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors filgrastim, recombinant interleukin-11 - Breast Cancer, Gestational Trophoblastic Tumor | Phase 2 | Completed | Fred Hutchinson Cancer Center | 2000-08-01 | 2010-04-02 |
von Willebrand Diseases (4) · Thrombocytopenia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Embryonal (1) · Carcinoma, Ovarian Epithelial (1) · Crohn Disease (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Endodermal Sinus Tumor (1) · Gestational Trophoblastic Disease (1) · Hematologic Diseases (1) · Hemophilia A (1)
Margaret Ragni (2) · The First Affiliated Hospital with Nanjing Medical University (2) · University of Pittsburgh (2) · Beijing Northland Biotech. Co., Ltd. (1) · Fred Hutchinson Cancer Center (1) · Liaoning Cancer Hospital & Institute (1) · M.D. Anderson Cancer Center (1) · Nanfang Hospital, Southern Medical University (1) · National Cancer Institute (NCI) (1) · Shanghai Children's Medical Center (1) · The First Affiliated Hospital of Soochow University (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1) · Zhejiang Cancer Hospital (1)
China (8) · United States (8)
Margaret V. Ragni, MD, MPH (3) · Jia Chen, Doctor (1) · Jorge E. Cortes, MD (1) · Leona A. Holmberg, MD, PhD (1) · Margaret V Ragni, MD, MPH (1) · Qifa Liu, MD (1) · Tang Jingyan, M.D. (1) · Thomas Witzig (1) · Xiaojing Xing (1)